



Press Release – For immediate release

## Record fundraising for Poietis on the crowdfunding platform WiSEED

Pessac and Toulouse, France, December 17th, 2015

Poietis, French leader of Bioprinting, continues its growth by closing a first round of financing of €2.5 million including a fundraising record of nearly €1 million via the crowdfunding platform WiSEED. The funds raised will be used to industrialize Poietis Laser-Assisted Bioprinting technology and bring to market its first bioprinted tissues.

This ambitious round A is conducted with WiSEED (leader and pioneer of equity crowdfunding, which is financing its 11th project in the health sector), Business Angels and historical shareholders. This capital increase of €1.2 million is complemented with grants, reimbursable advances and loans obtained from Bpifrance, the Conseil Régional d'Aquitaine, Banque Populaire Aquitaine Centre Atlantique, EADS Développement and Michelin Développement.

**This first round is on line with the quick start of the company** leader in 3D printing of biological tissues. Indeed, a year after its inception and initial financing (€600k), Poietis has already generated first interests from key accounts (as illustrated by the signing of a first co-development partnership with BASF), signed the exclusive worldwide license for the laser-assisted bioprinting technology, and obtained the issuance of two patents in the US and Japan. Employing 19 people, Poietis plans to gradually increase its workforce to 25 people in 2017.

Fabien Guillemot, President and Scientific Director of Poietis, comments: *"After laying the foundation of the company during our first year, we get the capacity through this fundraising to strengthen our technology leadership at international level in particular by developing our bioprinter dedicated to tissue production."*


Bruno Brisson, Director of Business Development and General Manager of Poietis, added: *"This fundraising will also allow us to validate our first products up to commercialization in 2017 to the dermo-cosmetic research centers. Finally, that gives us the necessary financial base to initiate new co-development with industry leaders in our markets."*

Thierry Merquiol, WiSEED co-founder says: *"WiSEED is very proud of the wisdom and the enthusiasm of its community of investors on the project presented by Poietis. This is a record fundraising in crowdfunding in terms of the amount and the number of subscribers. They are sensitive to projects with high social impact, have praised Poietis and anticipate its strong development in the bioprinting field"*.

Bioprinting, 3D printing of biological tissues, responds to major socio-economic challenges: reducing animal testing thanks to *in vitro* models allowing to evaluate efficacy and toxicity of cosmetic ingredients and active pharmaceutical compounds; drug discovery by producing predictive disease models; emergence of personalized medicine by making custom tissues from the patient cells; and regenerative medicine by fabricating custom grafts. Market perspectives associated with bioprinting were recently valued at close to €2 billion in 2020.

- + [INSERM Bioprinting Press File](#)
- + [Royal Society of Chemistry article on Bioprinting for cosmetics industry](#)
- + [Grand View Research market study on bioprinting](#)

*Figure 1. An engineer programs the laser-assisted bioprinter at Poietis labs*



**About Poietis :** [Poietis](#) offers innovative solutions (custom biological tissues) based on Laser-Assisted Bioprinting for cosmetics and pharmaceutical industries as well as for regenerative medicine centers. Created in September 2014 by Fabien Guillemot and Bruno Brisson and Winner of the French National Contest ILAB 2014 organized by the Ministry of Education and Research, Poietis values nearly 10 years of research conducted within INSERM and the University of Bordeaux. Poietis is the first company in the world working on Laser-Assisted Bioprinting, and holds the exclusive worldwide license, for this technology in all fields of application. As part of this fundraising, Poietis was supported by the Regional Agency [Agence Développement Innovation](#) and [McDermott, Will & Emery](#).

**About WiSEED :** [WiSEED](#) participates in the development of new investment models based on the "power of the crowd," or crowdfunding. Using Internet offered opportunities, participating finance model can democratize access to an asset class so far reserved for only certain circles. WiSEED gives individuals the opportunity to be players in the financing of real economy.

With over 57,000 registered investors, WiSEED (as part of a mission of adviser in participative investments) has, since July 2009, funded for more than €35 million in 90 projects with strong growth potential in the areas of health, ecological transition, digital and industry or real estate, for amounts between €100 000 and €1 million. Projects contributing to the health and e-health sectors account for over 20% of investments.

Contacts Presse Poietis :  
[contact@poietis.com](mailto:contact@poietis.com)  
Tel : +33 (0)5 35 54 47 28

Contacts Presse WiSEED :  
Céline PARDO - Agence Point Virgule  
[cpardo@pointvirgule.com](mailto:cpardo@pointvirgule.com)  
Tel : +33 (0)1 73 79 50 62  
Mob : +33 (0)6 52 08 13 66